• Odyssey Therapeutics announced published preclinical findings in The Journal of Immunology supporting TNFR2 agonism for autoimmune and inflammatory diseases.
• Treatment reduced autoimmune disease severity in mice while promoting stable, tissue-directed regulatory T cells; human-cell experiments supported similar effects.
• Tissue-directed differentiation observed in mice was not seen with an IL-2 mutein, suggesting potential differentiation from IL-2-based therapies.
• Investigational TNFR2 agonist OD-003 is expected to complete IND-enabling studies in the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100800PRIMZONEFULLFEED9874000) on November 10, 2026, and is solely responsible for the information contained therein.